Impaired learning and memory in Pitx3 deficient aphakia mice: A genetic model for striatum-dependent cognitive symptoms in Parkinson's disease

Disorders of the basal ganglia such as Parkinson's disease (PD) and Huntington's disease are commonly thought of primarily as motor disorders; however, the cognitive symptoms of these diseases such as executive dysfunction, learning, memory and attention deficits are prominent and often mo...

Full description

Saved in:
Bibliographic Details
Published inNeurobiology of disease Vol. 31; no. 3; pp. 406 - 412
Main Authors Ardayfio, Paul, Moon, JiSook, Leung, Ka Ka Amanda, Youn-Hwang, Dong, Kim, Kwang-Soo
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2008
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disorders of the basal ganglia such as Parkinson's disease (PD) and Huntington's disease are commonly thought of primarily as motor disorders; however, the cognitive symptoms of these diseases such as executive dysfunction, learning, memory and attention deficits are prominent and often more disabling than the hallmark motor symptoms. Cognitive features of PD are often neglected in preclinical studies of PD, likely due to the lack of available animal models to study them. Aphakia mice, which are deficient in the transcription factor Pitx3, model the selective nigrostriatal DA loss in PD. Here we report that aphakia mice are impaired in striatum-dependent cognitive tasks including rotarod learning, T-maze and inhibitory avoidance tasks, but not the striatum-independent social transmission of food preference task. These results suggest that some neuropsychiatric symptoms in PD are related to the pathophysiology of the disease rather than stress associated with disease burden, or medications used to treat PD. Furthermore aphakia mice may be used as a novel model of non-motor symptoms in PD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Mail Drop 0510, Indianapolis, IN 46285
ISSN:0969-9961
1095-953X
1095-953X
DOI:10.1016/j.nbd.2008.05.017